Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Written by Emily J. Thompson, Senior Investment Analyst

CYTH%

RFL0%

Source: Newsfilter

Updated: Mar 13 2025

0mins

Source: Newsfilter

Merger Announcement: Rafael Holdings, Inc. is set to finalize its merger with Cyclo Therapeutics in Q3 2025, focusing on the clinical program Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1 after shareholder approval.
Financial Results: For the second quarter of fiscal year 2025, Rafael reported a net loss of $4.6 million, attributed to unrealized losses on investments in Cyclo, while research and development expenses increased due to consolidated activities from Cornerstone and Day Three.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Faruqi & Faruqi Encourages Gauzy Investors to Discuss Claims

Faruqi & Faruqi Investigates Alexandria Real Estate Equities for Securities Fraud After 19% Stock Drop

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch